Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1.

Buckheit KW, Buckheit RW Jr.

Mol Biol Int. 2012;2012:781305. doi: 10.1155/2012/781305. Epub 2012 Jul 12.

2.

Clinical development of microbicides for the prevention of HIV infection.

D'Cruz OJ, Uckun FM.

Curr Pharm Des. 2004;10(3):315-36. Review.

PMID:
14754390
3.

An algorithm for the preclinical development of anti-HIV topical microbicides.

Buckheit RW Jr, Buckheit KW.

Curr HIV Res. 2012 Jan 1;10(1):97-104.

PMID:
22264051
4.

Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV.

Buckheit KW, Furlan-Freguia C, Ham AS, Buckheit RW.

Curr Top Med Chem. 2016;16(10):1118-34. Review.

PMID:
26324047
5.

Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.

Gupta SK, Nutan.

HIV AIDS (Auckl). 2013 Oct 22;5:295-307. doi: 10.2147/HIV.S39164. Review.

6.

The importance of the vaginal delivery route for antiretrovirals in HIV prevention.

Ferguson LM, Rohan LC.

Ther Deliv. 2011 Dec;2(12):1535-50. doi: 10.4155/tde.11.126. Review.

7.

Formulation and delivery of anti-HIV rectal microbicides: advances and challenges.

Nunes R, Sarmento B, das Neves J.

J Control Release. 2014 Nov 28;194:278-94. doi: 10.1016/j.jconrel.2014.09.013. Epub 2014 Sep 16. Review.

PMID:
25229988
8.

Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay.

Watson KM, Buckheit CE, Buckheit RW Jr.

Antimicrob Agents Chemother. 2008 Aug;52(8):2787-96. doi: 10.1128/AAC.01657-07. Epub 2008 Jun 16.

9.

Topical microbicides to prevent the transmission of HIV: formulation gaps and challenges.

Turpin JA.

Drug Deliv Transl Res. 2011 Jun;1(3):194-200. doi: 10.1007/s13346-011-0034-2. Epub 2011 May 21.

10.

Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system.

Machado A, Cunha-Reis C, Ara├║jo F, Nunes R, Seabra V, Ferreira D, das Neves J, Sarmento B.

Acta Biomater. 2016 Oct 15;44:332-40. doi: 10.1016/j.actbio.2016.08.018. Epub 2016 Aug 17.

PMID:
27544812
11.

Topical microbicides for prevention of sexually transmitted infections.

Obiero J, Mwethera PG, Wiysonge CS.

Cochrane Database Syst Rev. 2012 Jun 13;(6):CD007961. doi: 10.1002/14651858.CD007961.pub2. Review.

PMID:
22696373
12.

Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.

Friend DR, Kiser PF.

Antiviral Res. 2013 Sep;99(3):391-400. doi: 10.1016/j.antiviral.2013.06.021. Epub 2013 Jul 8. Review.

PMID:
23845918
13.

Non-specific microbicide product development: then and now.

Romano JW, Robbiani M, Doncel GF, Moench T.

Curr HIV Res. 2012 Jan 1;10(1):9-18. Review.

14.

Using modeling to help understand vaginal microbicide functionality and create better products.

Katz DF, Gao Y, Kang M.

Drug Deliv Transl Res. 2011 Jun;1(3):256-76. doi: 10.1007/s13346-011-0029-z. Epub 2011 May 17.

15.

Microbicides for the prevention of HIV infection in women: an overview of recent trials.

Rosenberg ZF, Nel A, Heyward W, Mitchnick M.

Curr Opin HIV AIDS. 2006 Nov;1(6):514-9. doi: 10.1097/01.COH.0000247386.62743.b4.

PMID:
19372855
17.

Microbicides in the prevention of HIV infection: current status and future directions.

Nuttall J.

Drugs. 2010 Jul 9;70(10):1231-43. doi: 10.2165/10898650-000000000-00000. Review.

PMID:
20568831
18.

Development of topical microbicides to prevent the sexual transmission of HIV.

Buckheit RW Jr, Watson KM, Morrow KM, Ham AS.

Antiviral Res. 2010 Jan;85(1):142-58. doi: 10.1016/j.antiviral.2009.10.013. Epub 2009 Oct 27. Review.

19.

A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model.

Patton DL, Sweeney YT, Paul KJ.

Sex Transm Dis. 2009 Jun;36(6):350-6. doi: 10.1097/OLQ.0b013e318195c31a.

20.

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.

Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R.

PLoS Med. 2008 Aug 5;5(8):e157; discussion e157. doi: 10.1371/journal.pmed.0050157.

Supplemental Content

Support Center